Provides Third Quarter 2017 Financial Results and Update

Provides Third Quarter 2017 Financial Results and Update

ZIONA, Israel, November 28, 2017 -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV, TASE: BVXV), a clinical stage biopharmaceutical

company focused on developing and commercializing M-001, a universal flu vaccine candidate, today announced its financial results

for the quarter ended September 30, 2017 and provided a business update.

Ron Babecoff, BiondVax's CEO, commented, "I am pleased that, once again we are meeting our objectives, increased

our financial resources, and are moving towards executing our late stage universal flu vaccine development program."

Quarter 2017 Financial Summary

are in New Israel Shekels (NIS) and convenience translation to $US is provided using the exchange rate of 3.529 (NIS/$US) as at

of September 30, 2017, BiondVax had cash and cash equivalents, short-term investments and marketable securities of NIS 78.09m

($22.13m) as compared to NIS 36.6m as of June 30, 2017.

is a biopharmaceutical company developing a universal flu vaccine. The vaccine is designed to provide multi-season protection

against most seasonal and pandemic human influenza virus strains. BiondVax's proprietary technology utilizes a unique combination

of conserved and common peptides from influenza virus proteins, activating both arms of the immune system for a cross-protecting

and long-lasting effect. BiondVax is traded on NASDAQ: BVXV and TASE: BVXV. For more information, please visit www.biondvax.com.

press release contains forward-looking statements within the meaning of the Private Litigation Reform Act of 1995. Words such

as "expect," "believe," "intend," "plan," "continue," "may,"

"will," "anticipate," and similar expressions are intended to identify forward-looking statements. These

forward-looking statements involve certain risks and uncertainties reflect the management's current views with respect to

certain current and future events and are subject to various risks, uncertainties and assumptions that could cause the results

to differ materially from those expected by the management of BiondVax Pharmaceuticals Ltd. risks and uncertainties include, but

are not limited to, the risk that drug development involves a lengthy and expensive process with uncertain outcome, the results

of the contemplated Phase 2 & 3 trials, delays

or obstacles in launching and/or successfully completing our clinical trials, the

impact of the global economic environment on the Company customer target base, the adequacy of available cash resource and the

ability to raise capital when needed. More detailed information about the risks and uncertainties affecting the Company is

contained under the heading "Risk Factors" in our Annual Report on Form 20-F for the year ended December 31, 2016

filed with the U.S. Securities and Exchange Commission, or SEC, which is available on the SEC's website, www.sec.gov,

and in the Company's periodic filings with the SEC and the Tel-Aviv Stock Exchange.

** Tables to Follow **

In thousands, except per share data

*) Represents an amount lower than NIS 1.

OF COMPREHENSIVE INCOME

thousands, except per share data